Table
2: Results
of meta-analysis for polymorphisms in USF1 and cancer susceptibility
Variables (rs2516839) |
Case/Control |
C
vs. T |
CC
vs. TT |
TC
vs. TT |
||||||||
|
|
OR (95% CI) |
Pa |
I2 (%) |
OR (95% CI) |
Pa |
I2 |
OR (95% CI) |
Pa |
I2 |
||
Total |
582/1115 |
1.392(1.203-1.612)* |
0.113 |
29.3 |
1.837(1.386-2.433)* |
0.243 |
8.6 |
1.301(1.017-1.665)* |
0.904 |
0.0 |
||
Source of
control |
|
|
|
|
|
|
|
|
|
|
||
HB |
428/955 |
1.373(1.164-1.620)* |
0.040 |
58.4 |
1.771(1.293-2.424)* |
0.110 |
37.0 |
1.264(0.958-1.669) |
0.936 |
0.0 |
||
Cancer Type
|
|
|
|
|
|
|
|
|
|
|
||
HCC |
248/260 |
1.655(1.284-2.135)* |
0.192 |
17.0 |
2.496(1.529-4.074)* |
0.445 |
0.0 |
1.363(0.895-2.077) |
0.717 |
0.0 |
||
|
Case/Control |
CC+TC
vs. TT |
CC
vs. TC+TT |
|
|
|
||||||
|
|
OR (95% CI) |
Pa |
I2 |
OR (95% CI) |
Pa |
I2 |
|
|
|
||
Total |
582/1115 |
1.486(1.185-1.863)* |
0.594 |
0.0 |
1.548(1.219-1.965)* |
0.155 |
21.4 |
|
|
|
||
Source of
control |
|
|
|
|
|
|
|
|
|
|
||
HB |
428/955 |
1.450(1.125-1.869) |
0.352 |
0.0 |
1.515(1.160-1.979)* |
0.058 |
52.1 |
|
|
|
||
Cancer Type
|
|
|
|
|
|
|
|
|
|
|
||
HCC |
248/260 |
1.727(1.184-2.519)* |
0.749 |
0.0 |
2.037(1.324-3.134)* |
0.228 |
9.7 |
|
|
|
||
Variables (rs2516838) |
Case/Control |
C
vs. T |
CC vs. TT |
CT
vs. TT |
||||||||
|
|
OR (95% CI) |
Pa |
I2 (%) |
OR (95% CI) |
Pa |
I2 (%) |
OR (95% CI) |
Pa |
I2 (%) |
||
Total |
428/954 |
1.004(0.564-1.788) |
0.020 |
66.6 |
0.938(0.309-2.850) |
0.070 |
48.3 |
1.096(0.565-2.127) |
0.049 |
54.9 |
||
|
Case/Control |
CC+CT
vs. TT |
CC
vs. CT+TT |
|
|
|
||||||
|
|
OR (95% CI) |
Pa |
I2 (%) |
OR (95% CI) |
Pa |
I2 (%) |
|
|
|
||
Total |
428/954 |
1.082(0.523-2.237) |
0.025 |
64.3 |
0.801(0.455-1.412) |
0.168 |
22.4 |
|
|
|
||
Variables (rs2774276) |
Case/Control |
C
vs. T |
CC
vs. TT |
CT
vs.TT |
||||||||
|
|
OR (95% CI) |
Pa |
I2 (%) |
OR (95% CI) |
Pa |
I2 |
OR (95% CI) |
Pa |
I2 |
||
Total |
428/954 |
0.914(0.804-1.040) |
0.430 |
0.0 |
0.701(0.460-1.068) |
0.560 |
0.0 |
0.966(0.851-1.096) |
0.597 |
0.0 |
||
|
Case/Control |
CC+CT
vs. TT |
CC
vs. CT+TT |
|
|
|
||||||
|
|
OR (95% CI) |
Pa |
I2 |
OR (95% CI) |
Pa |
I2 |
|
|
|
||
Total |
428/954 |
0.947(0.846-1.062) |
0.510 |
0.0 |
0.708(0.459-1.094) |
0.600 |
0.0 |
|
|
|
||
Variables (rs3737787) |
Case/Control |
Cvs.
T |
CC
vs. TT |
TC
vs. TT |
||||||||
|
|
OR (95% CI) |
Pa |
I2 (%) |
OR (95% CI) |
Pa |
I2 |
OR (95% CI) |
Pa |
I2 |
||
Total |
428/954 |
1.210(1.082-1.354)* |
0.421 |
0.0 |
1.325(1.003-1.751)* |
0.622 |
0.0 |
1.277(1.124-1.450)* |
0.380 |
0.0 |
||
|
Case/Control |
CC+CTvs.
TT |
CC
vs. TC+TT |
|
|
|
||||||
|
|
OR (95% CI) |
Pa |
I2 (%) |
OR (95% CI) |
Pa |
I2 |
|
|
|
||
Total |
428/954 |
1.227(1.105-1.362)* |
0.362 |
0.0 |
1.143(0.852-1.534) |
0.823 |
0.0 |
|
|
|
||
I2:
0–25, means no heterogeneity, 25–50 means modest heterogeneity, >50
means high heterogeneity, PCR-RFLP: polymerase chain reaction-restriction
fragment length polymorphism, Pa: P value of Q test for
heterogeneity test, * means statistically significant (P<0.05).